4/15
01:18 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $40.00. They now have an "outperform" rating on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $40.00. They now have an "outperform" rating on the stock.
4/15
08:11 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $45.00 price target on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $45.00 price target on the stock.
4/1
01:04 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at BMO Capital Markets from $70.00 to $63.00. They now have an "outperform" rating on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at BMO Capital Markets from $70.00 to $63.00. They now have an "outperform" rating on the stock.
4/1
11:03 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Jefferies Financial Group Inc. from $30.00 to $58.00. They now have a "buy" rating on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Jefferies Financial Group Inc. from $30.00 to $58.00. They now have a "buy" rating on the stock.
3/28
08:09 am
fdmt
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis [Yahoo! Finance]
Medium
Report
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis [Yahoo! Finance]
3/28
08:00 am
fdmt
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
High
Report
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
3/8
10:41 am
fdmt
Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2024 Featuring 843 Market Players - Deals Listed by Company A-Z, Headline Value, Therapeutic Area, and Technology Type [Yahoo! Finance]
Low
Report
Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2024 Featuring 843 Market Players - Deals Listed by Company A-Z, Headline Value, Therapeutic Area, and Technology Type [Yahoo! Finance]
3/8
10:07 am
fdmt
Asset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024: Trends, Deal Structure, Leading Deals by Value, Most Active Dealmakers, and More [Yahoo! Finance]
Low
Report
Asset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024: Trends, Deal Structure, Leading Deals by Value, Most Active Dealmakers, and More [Yahoo! Finance]
3/7
11:19 am
fdmt
Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Partnering Trends Report 2024: Analysis of Deals Signed by the World's Leading Life Science Companies Signed Since 2016 [Yahoo! Finance]
Neutral
Report
Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Partnering Trends Report 2024: Analysis of Deals Signed by the World's Leading Life Science Companies Signed Since 2016 [Yahoo! Finance]
3/7
04:46 am
fdmt
Analysis of Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology Signed During 2016-2024 [Yahoo! Finance]
Medium
Report
Analysis of Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology Signed During 2016-2024 [Yahoo! Finance]
3/4
08:00 am
fdmt
4DMT to Participate in Upcoming Investor Conferences
Medium
Report
4DMT to Participate in Upcoming Investor Conferences
3/3
09:23 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
3/2
04:51 am
fdmt
4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results [Yahoo! Finance]
3/1
08:13 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
2/29
04:26 pm
fdmt
4DMT Reports Full Year 2023 Financial Results and Operational Highlights [Yahoo! Finance]
Medium
Report
4DMT Reports Full Year 2023 Financial Results and Operational Highlights [Yahoo! Finance]
2/29
04:05 pm
fdmt
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
Medium
Report
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
2/26
05:37 am
fdmt
Diakonos Oncology Appoints Biotech Veteran Anthony Baldor as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Diakonos Oncology Appoints Biotech Veteran Anthony Baldor as Chief Financial Officer [Yahoo! Finance]
2/12
08:17 am
fdmt
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024 [Yahoo! Finance]
Medium
Report
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024 [Yahoo! Finance]
2/12
08:04 am
fdmt
Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]
Low
Report
Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]
2/12
08:00 am
fdmt
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
Low
Report
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
2/8
03:14 am
fdmt
Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc [Yahoo! Finance]
Medium
Report
Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc [Yahoo! Finance]
2/7
08:14 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $81.00 price target on the stock.
High
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $81.00 price target on the stock.
2/6
11:27 pm
fdmt
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
High
Report
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
2/6
09:31 am
fdmt
Thinking about trading options or stock in C3.ai, Meta Platforms, 4D Molecular Therapeutics, Li Auto, or Varonis Systems?
Low
Report
Thinking about trading options or stock in C3.ai, Meta Platforms, 4D Molecular Therapeutics, Li Auto, or Varonis Systems?
2/5
04:16 pm
fdmt
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]